Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

Eligibility Criteria: (Both groups) * Evidence of intraluminal pulmonary vein stenosis in \> 1 vessel * Evidence of myofibroblast neo-proliferation, if biopsies were obtained * Acceptable organ function includes: Creatinine \< 1.5 x normal for age. Bilirubin \< 1.5 x normal for age. ALT \< or = 5x normal ANC \> or = 1,500/mm3, Hemoglobin \> or = 10g/dl, Platelets \> or = 100,000/mm3. Group A Eligibility Criteria: (begin treatment with Gleevec® only) * Significant concomitant congenital heart defect * Disease severity for each vessel Category 5 or lower or Category 6 or 7 in no more than 1 vessel Group B Eligibility Criteria: (begin treatment with Gleevec® and Avastin®) * Primary PVS (i.e. without concomitant congenital heart defect or lung disease) * Significant concomitant lung disease * Patients with PVS and underlying CHD who have category 6 or 7 disease in at least 2 of their pulmonary veins even after surgical or cath-based interventions. * Accepted organ function includes: Urine protein \< 1